BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 17668566)

  • 21. An HIV-1 integrase genotype assay for the detection of drug resistance mutations.
    Hearps AC; Greengrass V; Hoy J; Crowe SM
    Sex Health; 2009 Dec; 6(4):305-9. PubMed ID: 19917199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance to HIV-1 integrase inhibitors: A structural perspective.
    Mouscadet JF; Delelis O; Marcelin AG; Tchertanov L
    Drug Resist Updat; 2010; 13(4-5):139-50. PubMed ID: 20570551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
    Canducci F; Sampaolo M; Marinozzi MC; Boeri E; Spagnuolo V; Galli A; Castagna A; Lazzarin A; Clementi M; Gianotti N
    AIDS; 2009 Feb; 23(4):455-60. PubMed ID: 19165083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of HIV-1 Natural Polymorphisms and Integrase-Resistance-Associated Mutations in African Children.
    Fofana DB; Diarra H; Guindo I; Savadogo MK; d'Almeida M; Diallo FI; Baldé A; Soulié C; Kone A; Marcelin AG; Maiga AI; Lambert-Niclot S; Maiga M; McFall S; Hawkins CA; Murphy RL; Sylla M; Katlama C; Holl JL; Calvez V; Morand-Joubert L
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolution of raltegravir resistance during therapy.
    Sichtig N; Sierra S; Kaiser R; Däumer M; Reuter S; Schülter E; Altmann A; Fätkenheuer G; Dittmer U; Pfister H; Esser S
    J Antimicrob Chemother; 2009 Jul; 64(1):25-32. PubMed ID: 19447792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors.
    Charpentier C; Laureillard D; Piketty C; Tisserand P; Batisse D; Karmochkine M; Si-Mohamed A; Weiss L
    AIDS; 2010 Mar; 24(6):867-73. PubMed ID: 20160635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel integrase inhibitors for HIV.
    Prada N; Markowitz M
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
    Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
    J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitors.
    Meixenberger K; Yousef KP; Smith MR; Somogyi S; Fiedler S; Bartmeyer B; Hamouda O; Bannert N; von Kleist M; Kücherer C
    Virol J; 2017 Nov; 14(1):223. PubMed ID: 29137637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potent inhibitors of HIV-1 integrase display a two-step, slow-binding inhibition mechanism which is absent in a drug-resistant T66I/M154I mutant.
    Garvey EP; Schwartz B; Gartland MJ; Lang S; Halsey W; Sathe G; Carter HL; Weaver KL
    Biochemistry; 2009 Feb; 48(7):1644-53. PubMed ID: 19178153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of primary mutations associated with integrase inhibitors among HIV-1 subtypes B, C, and F circulating in Brazil.
    Passaes CB; Guimarães ML; Fernandez SL; Lorete Rdos S; Teixeira SL; Fernandez JC; Morgado MG
    J Acquir Immune Defic Syndr; 2009 May; 51(1):7-12. PubMed ID: 19262402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.
    Hardy I; Brenner B; Quashie P; Thomas R; Petropoulos C; Huang W; Moisi D; Wainberg MA; Roger M
    J Antimicrob Chemother; 2015 Feb; 70(2):405-11. PubMed ID: 25281399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.
    Parczewski M; Bander D; Urbańska A; Boroń-Kaczmarska A
    BMC Infect Dis; 2012 Dec; 12():368. PubMed ID: 23259737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.
    Malet I; Wirden M; Fourati S; Armenia D; Masquelier B; Fabeni L; Sayon S; Katlama C; Perno CF; Calvez V; Marcelin AG; Ceccherini-Silberstein F
    J Antimicrob Chemother; 2011 Jul; 66(7):1481-3. PubMed ID: 21474479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.
    Salgado M; Toro C; Simón A; Garrido C; Blanco F; Soriano V; Rodés B
    J Clin Virol; 2009 Oct; 46(2):173-5. PubMed ID: 19625211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural polymorphisms of HIV-1 subtype-C integrase coding region in a large group of ARV-naïve infected individuals.
    Dimonte S; Babakir-Mina M; Aquaro S; Perno CF
    Infection; 2013 Dec; 41(6):1097-102. PubMed ID: 23620062
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic diversity on the integrase region of the pol gene among HIV type 1-infected patients naive for integrase inhibitors in São Paulo City, Brazil.
    Arruda LB; Fonseca LA; Duarte AJ; Casseb J
    AIDS Res Hum Retroviruses; 2010 Jan; 26(1):105-7. PubMed ID: 20055590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.
    Nguyen HL; Ruxrungtham K; Delaugerre C
    Intervirology; 2012; 55(4):287-95. PubMed ID: 22456540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
    Goethals O; Vos A; Van Ginderen M; Geluykens P; Smits V; Schols D; Hertogs K; Clayton R
    Virology; 2010 Jul; 402(2):338-46. PubMed ID: 20421122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of drug resistance-associated mutations in human immunodeficiency virus type 1 integrase derived from drug-naive individuals in Surabaya, Indonesia.
    Kotaki T; Khairunisa SQ; Sukartiningrum SD; Witaningrum AM; Rusli M; Diansyah MN; Arfijanto MV; Rahayu RP; Nasronudin ; Kameoka M
    AIDS Res Hum Retroviruses; 2014 May; 30(5):489-92. PubMed ID: 24328535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.